Evidence map›Paper›PMID 41901262›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Stratified Therapeutic Drug Monitoring Could Potentially Improve the Efficacy and Safety of Oxcarbazepine in Children with Epilepsy: Novel Insights from a Single-Center, Large-Sample, Retrospective Real-World Study.

Yi-Jing Liu, Xi-Li Sun, Yue Li, Xiao-Peng Lu, Chun-Feng Wu, Hu Guo, Feng Chen

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi-Jing LiuPharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.ORCID 0009-0000-9012-7643
Xi-Li SunPharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.ORCID 0009-0009-2396-3276
Yue LiPharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
Xiao-Peng LuDepartment of Neurology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
Chun-Feng WuDepartment of Neurology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
Hu GuoDepartment of Neurology, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.
Feng ChenPharmaceutical Sciences Research Center, Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing 210008, China.ORCID 0000-0003-4800-6762

Funding

Nanjing Municipal Health Science and Technology Development Special Fund-Key Medical Project No. ZKX24039the Chinese Youth Medical Innovation Research Program 2024VIII04the Key Medical Research Project of the Jiangsu Provincial Health Commission ZD2022053the Specially Appointed Medical Expert Project of the Jiangsu Commission of Health 2019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

10,11-dihydro-10-hydroxycarbamazepine (MHD)childrenepilepsyindividualized therapyoxcarbazepine (OXC)real-world studytherapeutic drug monitoring (TDM)

Identifiers

PMID41901262
PMCPMC13029625

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.